NEW YORK(GenomeWeb) – Melanoma test development firm DermTech has raised $2.4 million. 

DermTech disclosed the financing in a document filed with the US Securities and Exchange Commission earlier this week. In an email, DermTech CFO and Treasurer Steven Kemper told GenomeWeb that participants in the private financing round included existing investors. He added that the La Jolla, Calif.-based firm is launching its pigmented lesion assay and is currently testing the assay with certain US dermatologists with plans for a broader launch in the second half of this year. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.